The study evaluates the feasibility, safety, and efficacy of treating rGBM patients with MTX110. Also Read: Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday – Here ...
Market Cap as of October 5: 900.19 Million Average Analysts’ Target Price as of October 5: $22.62 Year to date Share Price Gain: 232.09% Perspective Therapeutics, Inc. (NYSE:CATX) is a promising ...